0001209191-20-018133.txt : 20200311 0001209191-20-018133.hdr.sgml : 20200311 20200311165345 ACCESSION NUMBER: 0001209191-20-018133 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200219 FILED AS OF DATE: 20200311 DATE AS OF CHANGE: 20200311 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hefti Franz CENTRAL INDEX KEY: 0001735529 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38939 FILM NUMBER: 20705944 MAIL ADDRESS: STREET 1: C/O ALZHEON, INC. STREET 2: 111 SPEEN STREET, SUITE 306 CITY: FRAMINGHAM STATE: MA ZIP: 01701 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Prevail Therapeutics Inc. CENTRAL INDEX KEY: 0001714798 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 430 EAST 29TH STREET, SUITE 940 CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: 917-336-9310 MAIL ADDRESS: STREET 1: 430 EAST 29TH STREET, SUITE 940 CITY: NEW YORK STATE: NY ZIP: 10016 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-02-19 0 0001714798 Prevail Therapeutics Inc. PRVL 0001735529 Hefti Franz C/O PREVAIL THERAPEUTICS INC. 430 EAST 29TH STREET, SUITE 940 NEW YORK NY 10016 0 1 0 0 Chief Development Officer Stock Option (Right to Buy) 16.91 2020-02-19 4 A 0 62200 0.00 A 2030-02-19 Common Stock 62200 62200 D 25% of the total number of shares underlying the option vest and become exercisable on February 19, 2021 and an additional 1/48th of the total number of shares underlying the option shall vest and become exercisable on the same date of each of the thirty-six (36) consecutive months thereafter subject, in all cases, to the Reporting Person providing continuous service with the Issuer on each such date. /s/ Alison Haggerty, Attorney-in-Fact 2020-03-11